NCT00082199
Completed
Phase 4
A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism
Otsuka Pharmaceutical Development & Commercialization, Inc.1 site in 1 country400 target enrollmentApril 2004
Overview
- Phase
- Phase 4
- Intervention
- Aripiprazole
- Conditions
- Alcoholism
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Assessment of abstinence from the consumption of alcohol during the study
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this clinical research study is to learn whether subjects treated with aripiprazole are able to abstain from alcohol use for a greater number of days than subjects treated with placebo. The safety of using aripiprazole will also be studied.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects with a diagnosis of alcohol dependence who want to stop using alcohol will be considered for the study.
Exclusion Criteria
- Not provided
Arms & Interventions
A1
Intervention: Aripiprazole
A2
Intervention: Placebo
Outcomes
Primary Outcomes
Assessment of abstinence from the consumption of alcohol during the study
Secondary Outcomes
- Assessment of alcohol use during the study and behavioral measures of substance abuse an dependence
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Study of Aripiprazole in Patients With Acute Bipolar ManiaBipolar DisorderNCT00097266Otsuka Pharmaceutical Development & Commercialization, Inc.615
Completed
Phase 3
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's TypeDementia, Alzheimer TypeNCT01438060Otsuka Pharmaceutical Development & Commercialization, Inc.232
Unknown
Phase 2
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine DependenceSchizophreniaCocaine DependenceNCT00737256Paul Saenger44
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I DisorderBipolar Disorder ManiaNCT00665366Otsuka Pharmaceutical Development & Commercialization, Inc.493
Completed
Phase 4
Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory SchizophreniaSchizophreniaNCT00328367Seoul National University Hospital61